Bone Density-Addressing Medical Foods

Sōlaria Biō Has Introduced a Product Named Bondia™

Sōlaria Biō's breakthrough product — which is dubbed Bondia™ — is classified as a medical food intended for the dietary management of bone density loss in postmenopausal women.

The Bondia™ formulation operates on the principle of the gut-bone axis. It aims to mitigate inflammatory processes that contribute to bone deterioration. The company cites a clinical study, which was published in a peer-reviewed journal, to support its claims. The study followed 286 postmenopausal women who were taking Bondia™ daily. It found that the medical food "significantly slowed bone loss compared to placebo in women with osteopenia or a BMI greater than/equal to 30."

Sōlaria Biō's Bondia™ represents a new category of intervention, one that is distinct from pharmaceutical drugs or standard dietary supplements. The medical food is positioned as a proactive option for a health issue that typically manifests before conventional screening begins.

Open at source ↗